High-throughput technologies will transform the way we diagnose and treat malignancies.
Leukemias and lymphomas are malignancies that arise from immune cells. The majority of these malignancies arise from B cells, a type of immune cell. Leukemias and lymphomas derived from B cells affect over 100,000 Americans every year. The majority of those patients will succumb to their disease. Dr. Dave's research is focused on the application of high-throughput technologies including microarrays and massively parallel sequencing to improve the diagnosis and treatment of leukemias and lymphomas.
Active efforts in the laboratory and clinic include:
Sandeep Dave completed an M.S. in Biomedical Engineering and was in the combined M.D./M.B.A. program at Northwestern University Medical School/Kellogg Graduate School of Management. After medical school, he completed a residency in internal medicine at Northwestern and a clinical and post-doctoral fellowship in hematology-oncology at the National Institutes of Health.
He was won many awards for his research and teaching including the prestigious Fellows Award in Research Excellence at the National Institutes of Health. His work is focused on the application of high throughput technologies to identify new therapeutic targets, as well as markers of diagnosis and prognosis in patients with leukemias and lymphomas.